Auto-anticorpos anti-β2-glicoproteína I e síndrome metabólica

Borges, Rodrigo; Bodanese, Luis Carlos; Mühlen, Carlos Alberto von; Repetto, Giuseppe; Viehe, Mario; Norman, Gary L.; Staub, Henrique Luiz

doi:10.1590/s0066-782x2011005000021

Cited by 8 publications

(4 citation statements)

References 21 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…metabolic, renal and infectious diseases). 32 – 34 An association with infections was shown since the early description of aCL antibodies. 35 , 36 Given the fact that infection is also considered as one of the possible second hits triggering APS, it is difficult to consider infection-induced aPL as totally innocent.…”

Section: Discussionmentioning

confidence: 99%

High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients

Elbagir

Elshafie

Elagib³

et al. 2020

Lupus

View full text Add to dashboard Cite

Objectives IgA antiphospholipid antibodies (aPL) are prevalent in systemic lupus erythematosus (SLE) patients of African American, Afro-Caribbean and South African origin. Nevertheless, data from North Africa are lacking, and most studies use manufacturer-suggested cut-offs based on Caucasian controls. Therefore, we compared aPL isotypes in Sudanese and Swedish SLE patients using nation-based cut-offs. Methods Consecutive SLE patients and age- and sex-matched controls from Sudan ( N = 115/106) and Sweden ( N = 340/318) were included. All patients fulfilled the 1982 American College of Rheumatology SLE classification criteria. Antiphospholipid syndrome–related events were obtained from patients’ records. IgA/G/M anticardiolipin and anti-β2 glycoprotein I (β2GPI) were analysed with two independent assays. IgA anti-β2GPI domain 1 (D1) was also investigated. Manufacturers’ cut-offs and the 95th and 99th percentile cut-offs based on national controls were used. Results Sudanese patients and controls had higher levels and were more often positive for IgA aPL than Swedes when using manufacturers’ cut-offs. In contrast, using national cut-offs, the increase in IgA aPL among Sudanese patients was lost. Occurrence of IgA anti-D1 did not differ between the countries. Venous thromboses were less common among Sudanese patients and did not associate with aPL. No clinical associations were observed with IgA anti-β2GPI in Sudanese patients. Thromboses in Swedes were associated with IgG/M aPL. Fetal loss was associated with aPL in both cohorts. Conclusions IgA anti-β2GPI prevalence was higher among Sudanese compared to Swedish patients when manufacturers’ cut-offs were used. This situation was reversed when applying national cut-offs. Anti-D1 was not increased in Sudanese patients. Previous studies on populations of African origin, which demonstrate a high prevalence of IgA aPL positivity, should be re-evaluated using a similar cut-off approach.

show abstract

Section: Discussionmentioning

confidence: 99%

High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients

Elbagir

Elshafie

Elagib³

et al. 2020

Lupus

View full text Add to dashboard Cite

show abstract

“…It is commonly known that aβ2GPI IgG/IgM antibodies play an important role in the clinical manifestation of APS. However, as demonstrated by several research groups aβ2GPI IgA antibodies may also be associated with ischemic stroke [101][102][103][104][105]. Arad et al found that aβ2GPI antibodies are not only a marker of APS but are also directly involved in the pathogenesis of thrombosis [106].…”

Section: Aβ2gpi and Arterial Thrombosismentioning

confidence: 97%

VWF, Platelets and the Antiphospholipid Syndrome

Huang

Ninivaggi

Chayouâ

et al. 2021

IJMS

View full text Add to dashboard Cite

The antiphospholipid syndrome (APS) is characterized by thrombosis and/or pregnancy morbidity with the persistent presence of antiphospholipid antibodies (aPLs). Laboratory criteria for the classification of APS include the detection of lupus anticoagulant (LAC), anti-cardiolipin (aCL) antibodies and anti-β2glycoprotein I (aβ2GPI) antibodies. Clinical criteria for the classification of thrombotic APS include venous and arterial thrombosis, along with microvascular thrombosis. Several aPLs, including LAC, aβ2GPI and anti-phosphatidylserine/prothrombin antibodies (aPS/PT) have been associated with arterial thrombosis. The Von Willebrand Factor (VWF) plays an important role in arterial thrombosis by mediating platelet adhesion and aggregation. Studies have shown that aPLs antibodies present in APS patients are able to increase the risk of arterial thrombosis by upregulating the plasma levels of active VWF and by promoting platelet activation. Inflammatory reactions induced by APS may also provide a suitable condition for arterial thrombosis, mostly ischemic stroke and myocardial infarction. The presence of other cardiovascular risk factors can enhance the effect of aPLs and increase the risk for thrombosis even more. These factors should therefore be taken into account when investigating APS-related arterial thrombosis. Nevertheless, the exact mechanism by which aPLs can cause thrombosis remains to be elucidated.

show abstract

“…With regard to disease associations of particular isotypes, an increased prevalence of IgA anti-B2GPI has been reported in a variety of disorders such as autoimmune hepatitis, coeliac disease, metabolic syndrome, and haemodialysed patients with end stage renal failure [36,37,38,39]. The significance of these associations remains unclear as the presence of anti-B2GPI is not always associated with APS manifestations.…”

Section: Anti-b2gpi Outside Of Aps: Questions Regarding Specificitymentioning

confidence: 99%

The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome

Brusch

2016

Antibodies

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a thrombophilic disorder that classically presents with vascular thrombosis and/or obstetric complications. APS is associated with antiphospholipid antibodies: a heterogeneous group of autoantibodies that are directed against membrane phospholipids in complex with phospholipid-binding proteins. Beta-2-glycoprotein I (B2GPI) binds anionic phospholipids and is considered to be the predominant antigen in APS and antibodies against B2GPI (anti-B2GPI) are recognised in the laboratory criteria for APS diagnosis. This review focuses on the part played by anti-B2GPI in the pathogenesis of APS, their associations with different clinical phenotypes of the disorder and new avenues for refining the diagnostic potential of anti-B2GPI testing.

show abstract

Auto-anticorpos anti-β2-glicoproteína I e síndrome metabólica

Cited by 8 publications

References 21 publications

High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients

High IgA antiphospholipid autoantibodies in healthy Sudanese explain the increased prevalence among Sudanese compared to Swedish systemic lupus erythematosus patients

VWF, Platelets and the Antiphospholipid Syndrome

The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome

Contact Info

Product

Resources

About